Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1612
    -0.0071 (-0.61%)
     
  • GBP/USD

    1.2371
    -0.0067 (-0.54%)
     
  • Bitcoin GBP

    51,891.93
    +713.93 (+1.39%)
     
  • CMC Crypto 200

    1,334.09
    +21.47 (+1.58%)
     
  • S&P 500

    4,959.68
    -51.44 (-1.03%)
     
  • DOW

    37,952.41
    +177.03 (+0.47%)
     
  • CRUDE OIL

    83.30
    +0.57 (+0.69%)
     
  • GOLD FUTURES

    2,407.00
    +9.00 (+0.38%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Management change

Chemometec A/S
Chemometec A/S

ANNOUNCEMENT NO. 233

14 December 2022



Management change

Steen Søndergaard has announced that he wants to resign from his position as CEO of ChemoMetec A/S.

It has been agreed that Steen Søndergaard remains in his position until a replacement has been found, however with resignation during the calendar year 2023 and possibly no later than 30 June 2023.

The search for a new CEO has been initiated, and the Board of Directors expects to announce the name of the new CEO during the first quarter of 2023.



For further information

Niels Thestrup, Chairman of the Board, ChemoMetec A/S
Phone: (+45) 3370 2000



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com